Geben Sie eine Aktie oder eine Kryptowährung in der Suchleiste an, um eine Zusammenfassung zu erhalten
China Isotope Radiation Corporation
1763China Isotope & Radiation Corporation engages in the research and development, manufacture, and sale of diagnostic and therapeutic radiopharmaceuticals and radioactive source products for medical and industrial applications in China. It operates through five segments: Pharmaceuticals; Radioactive Source Products; Irradiation; Radiation Therapy Equipment and Related Services; and Other Businesses. The Pharmaceuticals segment engages in the research, development, manufacture, and sale of imaging diagnostic and therapeutic radiopharmaceuticals; urea breath test kits and analyzers; and in vitro immunoassay diagnostic reagents and kits. The Radioactive Source Products segment sells medical and industrial radioactive sources products and related technical services. The Irradiation segment offers irradiation services to manufacturers of medical devices, food, traditional Chinese medicine, and cosmetics for sterilization; and EPC services for the design, manufacturing, and installation of gamma ray irradiation facilities. The Radiation Therapy Equipment and Related Services segment sells radiation therapy equipment; and provides related maintenance services. The Other Businesses segment provides independent clinical laboratory services for nuclear technology industry applications and medical product applications; and sells radiation therapy equipment and other miscellaneous services. In addition, the company engages in the production and sale of bio-pharmaceuticals. The company was founded in 1983 and is headquartered in Beijing, China. China Isotope & Radiation Corporation is a subsidiary of China National Nuclear Corporation. Address: No. 66 Changwa Middle Street, Beijing, China
Analytics
Zielpreis von Wall Street
261.24 HKDKGV
8.4Dividendenrendite
6.68 %Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Schlüsselzahlen 1763
Dividenden-Analyse 1763
Dividendenwachstum über 5 Jahre
183 %Kontinuierliches Wachstum
4 JahreAusschüttungsquote 5-Jahres-Durchschnitt
26 %Verlauf der Dividende 1763
Bewertung der Aktie 1763
Finanzen 1763
Ergebnisse | 2019 | Dynamik |